Nachrichten zur Bristol-Myers Squibb Co Aktie

FDA Ad Com set for Bristol-Myers luspatercept for MDS

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Bristol-Myers Squibb (BMY) closed at $57.41 in the latest trading session, marking a +0.83% move from the prior day....…

What Percent Does Bristol-Myers Squibb Spend On R&D, 30%, 40%, Or 50%-

Bristol-Myers Squibbs (NYSE: BMY) R&D expenses were 36% of its total revenues in 2018. Total expenses were largely driven by…

Sell Celgene, Buy Bristol-Myers: Counting Profits At Full Time - What To Do Now

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb Charts Prescribe Optimism in the Months Ahead

Um den gesamten Artikel unter realmoney.thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

CEO of drugmaker Bristol Myers sees real need for policy reform on prescription pricing

Bristol-Myers Squibb CEO Giovanni Caforio tells Jim Cramer that his company believes the affordability of prescription drugs is a problem.…

Bristol-Myers Play on 3 Drugs Is a Good Bet, Analyst Says

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Why Im Holding On to My Bristol-Myers Squibb Shares Now That the Celgene Acquisition Has Closed

There are two reasons this Fool isnt selling his newfound shares from the Celgene buyout....…

All Quiet At Bristol-Myers After Celgene Deal Finally Closes

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Melanoma Study Misses Goal, Closes Celgene Deal

Bristol-Myers (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients.…

Amgen erhöht nach Abschluss von Zukauf erneut die Jahresprognose

THOUSAND OAKS (dpa-AFX) - Der Biotechkonzern Amgen hebt nach der Übernahme eines Medikaments vom Rivalen…

Bristol-Myers Stock Is Rising After Celgene Buy Closes

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

$18.5B of Celgene notes tendered in Bristol-Myers exchange offer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Closes $74 Billion Celgene Takeover; Shares Gain

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb completes $74bn acquisition of biotechnology firm Celgene

With the closing of the acquisition, Celgene became a wholly-owned subsidiary of BMS. Under the deal, Celgene shareholders secured for…

Bristol-Myers finalizes Celgene buy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb completes $74 billion acquisition of Celgene

Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp. , nearly a year…

Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco

Zacks.com featured highlights include: Bristol-Myers Squibb, Urban Outfitters, Hewlett Packard, Cardinal Health and British American Tobacco...…

Bristol-Myers Squibb Has a Skin Cancer Trial Setback

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Thinking about buying stock in Aurora Cannabis, Advanced Micro Devices, Bristol-Myers Squibb, Nike, or Visa-

NEW YORK , Nov. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB,…

UPDATE 1-Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing…

Bristol-Myers Squibb Slides on Poor Skin Cancer Trial Results

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Opdivo + Yervoy disappoints in melanoma study

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers misses main goal of late-stage skin cancer trial

Bristol-Myers Squibb Co said on Wednesday its late-stage trial testing a combination of its cancer drugs missed a main goal of preventing…

Bristol-Myers stock slides premarket after melanoma trial fails to meet main goal

Bristol-Myers Squibb Co. shares slid 0.9% in premarket trade Wednesday, after the drug company said a trial of opdivo…

Celgene: Bargain Bin At Bristol-Myers Squibb Deal Closing

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ServiceNow stock up 4% on news it is joining the S&P 500

ServiceNow Inc. will replace Celgene Corp. in the S&P 500 index before the open on Thursday, S&P…

What Happened in the Stock Market Today

HP rejected a buyout offer from Xerox, and the merger of Bristol-Myers Squibb and Celgene will complete this week....…

At Long Last, Bristol-Myers Will Buy Celgene On Wednesday

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Should Value Investors Buy Bristol-Myers Squibb (BMY) Stock-

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgenes psoriasis drug Otezla,…

Bristol-Myers won U.S. antitrust approval for its acquisition of Celgene

Um den gesamten Artikel unter bloom.bg zu lesen, klicken Sie bitte auf die Überschrift...…

FTC makes Celgenes Otezla divestiture official condition for Bristol-Myers acquisition

Celgene Corp. is required to divest its most popular psoriasis treatment in order to be acquired by Bristol-Myers Squibb…

UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgenes psoriasis drug Otezla,…

Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they…

Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they…

FTC on board with Bristol-Myers/Celgene tie-up on Otezla sale

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Whats Bristol-Myers Squibbs Fair Stock Price Estimate Based On Expected 2019 Earnings-

Bristol-Myers Squibbs (NYSE: BMY) fair price estimate based on expected 2019 earnings is $59, according to Trefis estimates. This is…

Thinking about buying stock in Apple, Bristol-Myers Squibb, Cronos Group, Coca-Cola, or Walgreens Boots Alliance-

NEW YORK , Nov. 12, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL,…

Why Celgenes Latest FDA Approval Makes Bristol-Myers Squibbs Dividend Look Even Better

Good news for Celgene is good news for Bristol-Myers Squibb -- and investors who like the big drugmakers juicy dividend....…

Why Bristol-Myers Squibb Stock Gained 13% in October

Is Bristols stock still an attractive buy after last months uptick?...…

FDA accepts Bristol-Myers application for Opdivo + Yervoy for liver cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-U.S. FDA approves Celgenes rare blood disorder drug

The U.S. Food and Drug Administration said on Friday it had approved a treatment for a rare blood disorder from Celgene Corp,…

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo

The Zacks Analyst Blog Highlights: Pfizer, Merck, Bristol-Myers and Glaxo...…

Should Merck Investors Worry About Bristol Myers Lung Cancer Drug Results-

While the results are promising, are they enough to threaten Mercks cancer superdrug Keytruda?...…

Biotech Value Stocks Climb Out of Sick Bed

Recent good news from Biogen and Bristol-Myers Squibb bolsters hope that years of weak performance may be ending....…

Pharma Stock Roundup: MRK, PFE, GSK, BMY Q3 Earnings, Other Updates

Pfizer (PFE), Merck (MRK), Bristol-Myers (BMY) and others release Q3 results....…

Bristol-Myers (BMY) Hits Fresh High: Is There Still Room to Run-

Bristol-Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a…

Bristol-Myers extends exchange offer for Celgene debt

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers cancer drugs sales stall as Merck rival gains

Um den gesamten Artikel unter bloom.bg zu lesen, klicken Sie bitte auf die Überschrift...…